V-Bio Ventures - BioVox showcase

Event

Register now for Science for health 2022: Advancing Gene Therapy!

The 21st of November 2022, Science for health will plot the course for the Belgian life sciences ecosystem towards a bright future in gene therapy, based on expert insights into the field’s unique challenges and inspiring stories of success. The event will take place at SQUARE Brussels and online. […] November 21, 2022

V-Bio Ventures leads Sibylla Biotech's EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases

Ghent, Belgium, 4 October 2022 – V-Bio Ventures announces the successful close of a EUR 23 million Series A financing […] October 4, 2022 · V-Bio Ventures

VC opportunities for impact in the face of climate disaster

Venture capitalists have a vital role to play in guiding our planet’s future. By investing in technological advances that remediate […] September 7, 2022 · V-Bio Ventures

V-Bio Ventures portfolio company Biodol Therapeutics nominates its first preclinical candidate as a next-generation therapy for neuropathic pain

Ghent, Belgium, 31 August 2022 – V-Bio Ventures portfolio company Biodol Therapeutics, a French biotech company developing next-generation neuropathic pain […] August 31, 2022 · V-Bio Ventures

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

• Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs […] August 25, 2022 · V-Bio Ventures

Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease

Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The […] August 17, 2022 · V-Bio Ventures

Is the dot-com bubble bursting all over again?

The stock market value of biotech companies has been crashing lately, bitterly reminiscent of the dot-com bubble burst in the […] June 14, 2022 · V-Bio Ventures

Dualyx: restoring the body’s balance in autoimmune diseases

Belgian start-up Dualyx is developing a novel approach with the potential to treat a wide range of autoimmune disorders. The […] May 12, 2022 · V-Bio Ventures

Drug development trends: from common to orphan indications… and back again?

Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to […] April 20, 2022 · V-Bio Ventures

V-Bio Ventures raises EUR 110 million for its second fund and expands team

Ghent, Belgium, 31 March 2022 – V-Bio Ventures announced the final closing of its second fund, V-Bio Fund 2, having […] March 31, 2022 · V-Bio Ventures

Antimicrobial Resistance – the hidden killer we’re ignoring

Antimicrobial Resistance has become an enormous challenge for global health, yet remains largely ignored by companies. As this deadly race […] March 16, 2022 · V-Bio Ventures

V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals

Ghent, Belgium, 16 March 2022 – V-Bio Ventures today announced the completion of a EUR 80 million Series B round […] March 16, 2022 · V-Bio Ventures

V-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio

Ghent, Belgium, 1 March 2022 – V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi […] March 1, 2022 · V-Bio Ventures

When should a biotech hire a CFO?

February 16, 2022 · V-Bio Ventures

V-Bio Ventures raises additional capital to support young biotech companies

Ghent, Belgium, 27 January 2022 – V-Bio Ventures, a venture capital company that focuses specifically on the segment of young […] January 27, 2022 · V-Bio Ventures

Economic Success: infinite growth is only possible in a diverse ecosystem

In recent public discussions on economic progress, people have been asking: is infinite growth really the best way to measure […] January 26, 2022 · V-Bio Ventures

Long COVID: what it means for the life sciences industry and other chronic conditions

Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although […] December 15, 2021 · V-Bio Ventures

V-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria Pharmaceuticals

Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart […] December 9, 2021 · V-Bio Ventures

Confo-dently into the future!

Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, […] November 24, 2021 · V-Bio Ventures

New GMOs on the horizon: say ‘cheese’!

To meet the challenges of climate change and global food demand, more VCs are investing in AgTech companies. A lot […] October 20, 2021 · V-Bio Ventures

Biogen’s controversial Alzheimer’s drug approved by the FDA – what now?

It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug […] September 22, 2021 · V-Bio Ventures

Cancer diagnosis and therapy in one: Precirix tackles tumors with camelid antibodies

A new drug that can identify tumors, trace metastases, and treat cancer – all in one? Belgian start-up Precirix is […] August 18, 2021 · V-Bio Ventures

Moderna: from secretive platform company to vaccine superstar

Moderna Therapeutics has never really been a typical biotech. Sure, nowadays it is world famous thanks to its COVID-19 vaccine, […] June 23, 2021 · V-Bio Ventures

Friend or foe: building a healthy relationship with your board

CEOs of start-ups face many challenges. Among many tasks, they have to set up the organization, write the business plan, […] June 23, 2021 · V-Bio Ventures

To fund or not to fund: the psychology of investment decisions

Much has been written about the psychology of decision making and how venture capitalists choose which companies they want to […] April 28, 2021 · V-Bio Ventures

V-Bio Ventures invests in new start-up Protealis to uplift sustainable plant protein production

Ghent, Belgium, 8 April 2021 – Today V-Bio Ventures announces its investment in Ghent-based company Protealis, a new spin-off from […] April 8, 2021 · V-Bio Ventures

AgomAb’s journey of growth in regenerative medicine

Ghent-based AgomAb Therapeutics recently raised a Series B of $74 million, the largest round ever for a Belgian biotech in […] March 31, 2021 · V-Bio Ventures

V-Bio Ventures: a fresh fund with a difference

V-Bio Ventures recently announced their second fund, with the first closing already totaling 78 million euros [final close at 110 […] February 24, 2021 · V-Bio Ventures

V-Bio Ventures launches its second fund at EUR 78 million

– First Closing of V-Bio Fund 2 is announced at EUR 78 million – V-Bio Fund 2 will ensure seamless […] February 4, 2021 · V-Bio Ventures

How to build the right team for start-up success

One of the key ingredients to start-up success is a stellar management team. Attracting (and retaining) the right kind of […] January 27, 2021 · V-Bio Ventures

Decades-old discoveries cause paradigm shifts in modern medicine

Complete paradigm shifts in medicine are rare, but there have nevertheless been several major examples in the past hundred years. […] December 16, 2020 · V-Bio Ventures

An insightful solution to eye injections

Developing new therapies is sometimes not enough: for retinal indications, accurate delivery is key to making a drug work. Lowering […] November 4, 2020 · V-Bio Ventures

V-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals

Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR […] October 27, 2020 · V-Bio Ventures

Can Darwin’s theory explain why we get sick?

While physicians care for their individual patients and are interested in the factors contributing to the individual’s condition, evolutionary biologists […] September 30, 2020 · V-Bio Ventures

A novel approach to neurology could bring relief to people in pain

In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to […] August 31, 2020 · V-Bio Ventures

Drug combos: how much is 1 + 1?

Many of our current antiviral, antibacterial and anti-tumour medications are comprised of combinations of two or three active substances, selected […] August 31, 2020 · V-Bio Ventures

Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures

V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures

V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19

Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. […] July 28, 2020 · V-Bio Ventures

The opioid epidemic: solutions to a painful problem

Opioid misuse is a public health crisis that has resulted in debilitation, deaths, and significant social and economic impact. The […] July 7, 2020 · V-Bio Ventures

How changing diets gave rise to the world’s deadliest diseases

In a recent article, we discussed how the most prescribed drugs are usually indicated for common noncommunicable diseases. These include […] June 8, 2020 · V-Bio Ventures

Cell therapies: opportunities and challenges

This article was authored by Christina Takke from V-Bio Ventures. Recent activities in the cell therapy field have prompted many […] May 5, 2020 · V-Bio Ventures

Potential impact of the corona crisis on the life sciences industry

This article was authored by Christina Takke from V-Bio Ventures Over the past few months, every news headline has focused […] March 26, 2020 · V-Bio Ventures

Augustine Therapeutics: bridging the valley of death with VIB Discovery Sciences

Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding [...] February 26, 2020 · V-Bio Ventures

Why Are Start-Ups Such Hotbeds For Innovation?

A large proportion of new treatments and life sciences breakthroughs can often be traced back to humble beginnings in a […] January 20, 2020 · V-Bio Ventures

V-Bio Ventures invests in RootWave in a EUR 6.5 M Series A financing to develop and market electrical weed killing solutions

Today V-Bio Ventures announces its investment in RootWave, a pioneer in electrical weed killing solutions. RootWave secured ca. EUR 6.5m in a Series A investment round [...] January 20, 2020 · V-Bio Ventures

How business models shaped our current drug development trends

December 17, 2019 · V-Bio Ventures

V-Bio Ventures invests in Augustine Therapeutics, a VIB and KU Leuven spin-off to fight neuromuscular diseases

Ghent, Belgium, December 16 2019 – Today V-Bio Ventures announces its investment in Augustine Therapeutics, a new venture developing innovative […] December 16, 2019 · V-Bio Ventures

Magic mushrooms in modern medicine

This article was authored by Katja Rosenkranz from V-Bio Ventures. More than 75 years after the initial discovery of lysergic acid […] November 26, 2019 · V-Bio Ventures

Mining the microbiome for sustainable agriculture solutions

In this month’s article we take a look at Aphea.Bio, a V-Bio Ventures portfolio company. This startup is developing microbiome […] October 24, 2019 · V-Bio Ventures

Closing the gender gap in biotech funding: a follow-up study

This article was authored by Christina Takke from V-Bio Ventures. In this follow-up to a previous VC Views article, V-Bio […] September 24, 2019 · V-Bio Ventures

The million-dollar question: How much do you charge for a lifesaving drug?

The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags [...] August 26, 2019 · V-Bio Ventures

How do we reduce the high cost of clinical trials?

Drug development is an exorbitantly expensive endeavor. A large expense factor for developing a new therapy is the high cost of conducting clinical trials. [...] July 18, 2019 · V-Bio Ventures

Betting big on blood screens for early cancer detection

This article was authored by Ward Capoen from V-Bio Ventures. The American Society of Clinical Oncology (ASCO) just held their […] June 27, 2019 · V-Bio Ventures

OCTIMET Oncology tackling cancer with a new captain at the helm

In this article, V-Bio Ventures introduces one of their portfolio companies, OCTIMET. This Belgian oncology startup just added a new […] May 29, 2019 · V-Bio Ventures

Cultured meat, plant-based patties and bug burgers: VCs are backing protein alternatives

When it comes to food, our key sources of nutrition haven’t changed much in the last ten thousand years. Though hyped-up food trends and diets come and go, [...] April 16, 2019 · V-Bio Ventures

Closing the gender gap in biotech funding

Companies with a good gender balance consistently outperform those with only men in their management teams. [...] March 19, 2019 · V-Bio Ventures

Life after a PhD: alternatives to academia

This article was authored by Rishabh Chawla from V-Bio Ventures. Having finished a PhD in life sciences can often leave […] February 19, 2019 · V-Bio Ventures

Are we spending too much money on cancer drugs?

This article was authored by Ward Capoen from V-Bio Ventures. November is classically the month where immunotherapy takes center stage, […] January 22, 2019 · V-Bio Ventures

Why start-ups can become mega companies in the pharma sector

In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully […] November 20, 2018 · V-Bio Ventures

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) – V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals Camel-IDS […] November 15, 2018 · V-Bio Ventures

Are tech investments under threat by anti-science sentiments?

In biotech, company creation is usually preceded by scientific discoveries presenting solutions to existing problems. Because of this, early stage […] October 30, 2018 · V-Bio Ventures

Bringing clinical trials into the home

Lowering the costs of drug development is more important than ever; with the increasing pressure on drug pricing and billions […] October 2, 2018 · V-Bio Ventures

V-Bio Ventures participates in 22.5 million euros series B financing round of Horama

Ghent (Belgium), September 18th, 2018 – The Belgian life sciences venture fund V-Bio Ventures (www.v-bio.ventures) today announces that it joins […] September 18, 2018 · V-Bio Ventures

Forever young: the science of aging well

“Is aging a disease?” For a long time, the answer to this question seemed obvious: aging is a natural thing […] August 28, 2018 · V-Bio Ventures

Biotechs and subsidies - a fraught relationship

The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. […] July 23, 2018 · V-Bio Ventures

Acquisitions of Biotech companies: a good or a bad thing?

When on the 8th January 2018 the news travelled that Novo Nordisk made a €2.6bn bid for Belgium’s Ablynx, only […] May 14, 2018 · V-Bio Ventures

How to build a “European Amgen”

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world. Only […] April 19, 2018 · V-Bio Ventures

Is innovation killing the pharmaceutical industry?

In the past few years, the speed at which new drugs have been coming to the market has accelerated significantly […] March 18, 2018 · V-Bio Ventures

Artificial intelligence beyond the hype: achievements and expectations in the biotech space

Artificial intelligence (AI) is a term that pops up everywhere lately. In this article, we provide some examples of how […] January 18, 2018 · V-Bio Ventures

New cures for hereditary diseases around the corner?

Hereditary diseases are caused by mutations or deletions in (single) genes that lead to either dysfunctional or inadequate levels of […] December 18, 2017 · V-Bio Ventures

Belgium vs Germany in the Life Sciences start-up championship

Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when […] November 20, 2017 · V-Bio Ventures

How Aphea.Bio managed to gather the funds to transcend from academia to industry

Aphea.Bio is an agriculture startup, originating from the VIB and flourishing underneath the wings of V-Bio Ventures. Steven Vandenabeele (CTO […] October 16, 2017 · V-Bio Ventures

The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects […] September 11, 2017 · V-Bio Ventures

Aphea.Bio aims at leading position in next generation agricultural biologicals

Aphea.Bio focusses on plant-bacterial interactions for the development of biopesticides and biostimulants based on naturally occurring microorganisms.

July 7, 2017 · V-Bio Ventures

Strengthening communication in biotech companies

Many biotech management teams fail to reach out to investors in a clear and appealing way.

May 22, 2017 · V-Bio Ventures

Curing all diseases in the next 20 years: the new hype amongst billionaires?

Despite the initial intent of charitable foundations to be not-for-profit, some of them tend to morph into organizations with bigger aspirations.

April 17, 2017 · V-Bio Ventures

Investing in European biotech faced with many challenges

Investing in biotech companies is a capital-intensive and risky business, and it’s no secret that more money and less risk-averse investors are available in the US than in Europe. To keep innovations, companies, and their economic benefits from being transferred to regions outside Europe, many national and international European initiatives are in place. The question remains whether this is sufficient to fundamentally improve Europe’s currently underfunded biotech ecosystem. The biotech investment specialists of V-Bio Ventures take us through Europe’s biotech investment landscape.

March 16, 2017 · V-Bio Ventures

Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company will build an atlas of DNA found in the blood, convinced major investors, such as Bill Gates and Jeff Bezos, of the technology’s potential. A whopping $1 billion was gathered in the company’s series B financing round. Yet, do Grail and its technology deserve this huge ticket?

March 15, 2017 · V-Bio Ventures

OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors

Octimet Oncology announced today that it has completed its series A investment round. The cancer start-up was able to secure […] January 18, 2017 · V-Bio Ventures

Mosquito Wars

Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Widely different companies are tackling the problem of mosquito control from very different angles; who will be successful in getting a grip on these tiny flying terrors? A view by V-Bio Ventures.

January 12, 2017 · V-Bio Ventures